3 top FTSE 100 shares I’d buy in July

These FTSE 100 shares should perform well in the future despite today’s uncertain outlook, says Roland Head.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

Should you be buying shares when the economic outlook is so uncertain? Absolutely! I’ve found a number of FTSE 100 shares that I think will deliver strong returns to long-term investors from current levels.

Healthcare heavyweight

If you’re building a diversified, long-term portfolio, I think you need to have some exposure to the healthcare sector. It’s an essential global business for which I believe demand will only grow.

My top FTSE 100 pick in this sector is pharmaceutical giant GlaxoSmithKline (LSE: GSK). Alongside its prescription medicine and vaccine businesses, the group also has a large consumer healthcare business — home to brands such as Sensodyne and Nicorette.

Glaxo plans to seperate its consumer business into a new company over the next couple of years. This will dividen the group into two smaller and more focused businesses. I think this will improve their growth potential — good news for shareholders.

The GSK share price has now fallen by nearly 15% from the highs seen earlier this year. The shares now trade on about 13.5 times forecast earnings, with a 5% dividend yield. I think this FTSE 100 share is priced to buy.

A FTSE 100 share for tech investors

Big tech stocks are rare in the UK. One exception is cyber security software group Avast (LSE: AVST). This Prague-based firm only floated on the London market in 2018, but its continued growth has already lifted it into the FTSE 100. I think there could be more to come.

Avast’s core anti-virus product has a free version, which the firm uses to recruit users to whom it can sell additional services. The group also has a corporate business. This might sound like a small operation but it’s not — Avast has over 435m active users and generated revenue of $873m in 2019.

Operating profit margins are high, at around 40%. Cash generation is good too, which means the group’s after-tax profits are reliably converted into spare cash. The only criticism I’d make is that the firm’s growth rate is relatively low — adjusted profits rose by just 8% last year.

Despite this, I think Avast’s strong financial performance and large customer base should support continued growth. The shares currently trade on about 20 times forecast earnings, with a dividend yield of around 2.1%. I think that’s a fair price to pay for this high quality FTSE 100 share.

A fashion stock you can trust

When you invest in a company there’s always an element of risk. As outsiders we never know everything about a business. One company that tries hard to provide a level playing field is retailer Next (LSE: NXT), which is known for the quality of its financial reporting.

The bad news is that Next’s management expect sales to fall by between 30% and 40% this year. As a result, pre-tax profits are expected to fall from £728m last year to a maximum of £150m.

However, there’s good news too. Careful management means that the group’s financial position remains very strong. Net debt is actually expected to fall this year.

Another attraction is that broker forecasts suggest profits will bounce back quickly next year. If they’re correct, then this FTSE 100 share now trades on just 13 times forecast earnings.

Next is a highly profitable business with an excellent track record of shareholder returns. I’d rate the shares as a buy at this level.


Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head owns shares of GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK owns shares of Next. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Abstract bull climbing indicators on stock chart
Investing Articles

Could the Chancellor’s Leeds Reforms trigger a bull market for UK stocks?

More competitive lending and greater interest in shares could help kick start growth for UK businesses. But could it also…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

I think this AI stock could double before Palantir

Palantir stock is up almost 100% this year. As a result, it now sports a market cap of $350bn meaning…

Read more »

Elevated view over city of London skyline
Investing Articles

As the FTSE 100 hits an all-time high, is it time to reconsider the S&P 500?

Christopher Ruane explains why a surging FTSE 100 has not yet made him focus more on the potential of S&P…

Read more »

GSK scientist holding lab syringe
Investing Articles

The FTSE 100 sits at a record high. But some stocks still look dirt cheap!

The usually sluggish FTSE 100 is having a surprisingly good year. But our writer feels there are still potential bargains…

Read more »

Close-up of British bank notes
Investing Articles

With a £20k Stocks and Shares ISA, here are 3 ways an investor could target a £2k annual passive income

Our writer thinks there is more than one way to try and skin a cat when it comes to earning…

Read more »

Businessman using pen drawing line for increasing arrow from 2024 to 2025
Investing Articles

Up 350% in 3 years but my favourite FTSE growth share is still on a low P/E of just 10!

Harvey Jones can't tear his eyes away from this former penny stock turned growth share superpower. But can it carry…

Read more »

Santa Clara offices of NVIDIA
Investing Articles

Up 83% in months, could Micron stock be the next Nvidia?

Chipmaker Micron Technology's stock price has surged by over 80% in just a few months. Could this be a possible…

Read more »

Tesla car at super charger station
US Stock

£1k invested in Tesla stock at the start of the year is currently worth…

Jon Smith reveals the performance of Tesla stock in 2025 and explains why he doesn't believe the move lower is…

Read more »